Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol 2011 Sep;86(9):804-6
Date
08/05/2011Pubmed ID
21815183Pubmed Central ID
PMC3804029DOI
10.1002/ajh.22101Scopus ID
2-s2.0-80051815757 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
Hydroxyurea (HU) is underutilized in sickle cell disease (SCD). Patient adherence with taking HU and with required drug monitoring is a provider perceived barrier to HU utilization.(1-4) To determine process issues that may contribute to these barriers we sought to: 1) describe how providers monitor and adjust HU dosing in children with SCD in clinical practice and 2) identify providers' methods of assessing HU adherence. A pilot-tested survey was emailed to American Society of Pediatric Hematology/Oncology (ASPHO) members. Descriptive statistics were performed. Thirty-one percent (n=350) of 1128 surveys were returned; 63% (220 of 350) of respondents provided care for children with SCD. Most providers (64.7%) follow labs monthly and almost half (41.9%) see patients monthly. The majority (61.9%) adjusted HU dosing using maximum tolerated dose commonly determined using ANC (27.9%), platelets (26.5%), and WBC count (11.2%). Adherence was primarily assessed using patient interview (84.2%), MCV (75.3%), and HbF levels (70.7%). The majority of providers perform monthly monitoring and assess HU adherence using unreliable methods. Determining optimal frequency of monitoring HU and more reliable methods of assessing adherence are essential to balancing safety and the elimination of barriers to promote HU utilization.
Author List
Brandow AM, Panepinto JAAuthor
Amanda Brandow DO Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Anemia, Sickle CellAntisickling Agents
Child
Cross-Sectional Studies
Drug Monitoring
Electronic Mail
Erythrocyte Indices
Fetal Hemoglobin
Humans
Hydroxyurea
Leukocyte Count
Maximum Tolerated Dose
Medication Adherence
Neutrophils
Platelet Count
Practice Patterns, Physicians'
Surveys and Questionnaires
Time Factors
United States
